Evidence map›Paper›PMID 28331852›Full record

ArticleBioMed research international2017

Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers.

Yong-Jun Tang, Kai Hu, Wei-Hua Huang, Chong-Zhi Wang, Zhi Liu, Yao Chen, Dong-Sheng Ouyang, Zhi-Rong Tan, Hong-Hao Zhou, Chun-Su Yuan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trimethylamine-Annals of medicine · 2025
    Review
  2. Rapid detection ofMolecular medicine reports · 2022
    Article
  3. Influence ofFrontiers in pharmacology · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Yong-Jun TangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China; Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China.
Kai HuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha 410078, China.
Wei-Hua HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China; Tang Center for Herbal Medicine Research, The Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 4028, Chicago, IL 60637, USA.ORCID 0000-0003-4167-8304
Chong-Zhi WangTang Center for Herbal Medicine Research, The Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 4028, Chicago, IL 60637, USA.ORCID 0000-0002-0950-2109
Zhi LiuTang Center for Herbal Medicine Research, The Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 4028, Chicago, IL 60637, USA.
Yao ChenDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
Dong-Sheng OuyangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
Zhi-Rong TanDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.ORCID 0000-0002-0420-6298
Hong-Hao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
Chun-Su YuanTang Center for Herbal Medicine Research, The Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, MC 4028, Chicago, IL 60637, USA.ORCID 0000-0002-0711-2342
Central South University · CNUniversity of Chicago · US

Funding

Center for Herbal Research on Colorectal CancerP01AT004418 · NCCIH · UNIVERSITY OF CHICAGO · PI YUAN, CHUN-SU · 2008 to 2012
$5.9M
Chemoprevention of Active Scutellaria baicalensis Fraction on Colon CancerK01AT005362 · NCCIH · UNIVERSITY OF CHICAGO · PI WANG, CHONG-ZHI · 2010 to 2014
$486k
NCCIH NIH HHS K01 AT005362NCCIH NIH HHS P01 AT004418
6 · The paper itself

Abstract

Sulindac is a nonsteroidal anti-inflammatory drug, which is clinically used for the ailments of various inflammations. This study investigated the allele frequencies of FMO3 E158K and E308G and evaluated the influences of these two genetic polymorphisms on the pharmacokinetics of sulindac and its metabolites in Chinese healthy male volunteers. Eight FMO3 wild-type (FMO3

Indexed as

AdultAnti-Inflammatory Agents, Non-SteroidalGene FrequencyGenotypeHealthy VolunteersHumansInflammationLinkage DisequilibriumMaleOxygenasesPolymorphism, Restriction Fragment LengthSulindacAnti-Inflammatory Agents, Non-Steroidaldimethylaniline monooxygenase (N-oxide forming)OxygenasesSulindacsulindac sulfidesulindac sulfone

Identifiers

PMID28331852
PMCPMC5346382
OpenAlexW2589545840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.